Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

SCOTUS Saves Obamacare, But More Change Is Needed

What a relief, that the U.S. Supreme Court ruled favorably on the Affordable Care Act, that people living in states without exchanges can receive subsidies for insurance through federal exchanges. Great! Because without that support, millions would miss meeting payments on their premiums. Despite its imperfectness, the ACA supports health care access for all. It’s […]

Read More »

Vitae-Boehringer diabetes drug fails as add-on therapy in trial

Vitae Pharmaceuticals Inc said its drug to treat type 2 diabetes in overweight patients did not meet its main goal in a mid-stage study testing it as an add-on therapy. The drug, being co-developed with German drugmaker Boehringer Ingelheim, was tested as an add-on therapy to metformin, a commonly prescribed diabetes drug. The blood sugar […]

Read More »

Egalet says drug less likely to be abused than other painkillers

Egalet Corp said data showed its experimental painkiller was less likely to be abused than a form of morphine already being sold. A study showed recreational opioid users did not like and were less prone to snort the company’s painkiller, Egalet-001, than MS Contin. Egalet’s study results come a week before a panel of experts […]

Read More »

High Blood Pressure Linked To Lower Alzheimer’s Risk, Brigham Young University Study

High Blood Pressure Associated With Lower Risk For Alzheimer’s A study coauthored by a BYU professor and a BYU undergraduate suggests that people with a genetic predisposition to high blood pressure have a lower risk for Alzheimer’s disease. However, authors conclude the connection may have more to do with anti-hypertension medication than high blood pressure […]

Read More »

A Gel That Can Make Drugs Last Longer, A*STAR Study

Researchers at the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR have developed a drug-delivering hydrogel to treat chronic diseases such as hepatitis C, a liver disease that kills around 500,000 people worldwide every year. “The new gel from IBN prevents premature drug release in the body. This allows for long-term drug delivery and reduces […]

Read More »

University of Southern California Scientists Look Into Why Most Alzheimer’s Patients Are Women

Nearly two-thirds of Americans with Alzheimer’s disease are women, and now some scientists are questioning the long-held assumption that it’s just because they tend to live longer than men. What else may put woman at extra risk? Could it be genetics? Biological differences in how women age? Maybe even lifestyle factors? Finding out might affect […]

Read More »

Middle Age Memory Failures Can Predict Alzheimer’s 18 Years Before Diagnosis, Rush University Medical Center Study

Results from an extensive new study suggest that early symptoms of Alzheimer’s disease appear up to 18 years before the disease is officially diagnosed. Researchers publishing in the journal Neurology gave 2,125 people, average age 73, a test of memory and thinking skills every three years for 18 years. All of the participants were either […]

Read More »

Compound In Magnolia May Combat Head And Neck Cancers, University of Alabama at Birmingham Study

Magnolias are prized for their large, colorful, fragrant flowers. Does the attractive, showy tree also harbor a potent cancer fighter? Yes, according to a growing number of studies, including one from VA and the University of Alabama at Birmingham that is now online in the journal Oncotarget. The study focused on squamous cell head and […]

Read More »

Merck & Co. Slashes Contractor Positions at Durham Vaccine Manufacturing Plant

June 29, 2015By Alex Keown, Breaking News Staff DURHAM, N.C. – Merck & Co. (MRK) terminated an unknown number of independent contractors this week at the pharmaceutical giant’s vaccine manufacturing site in central North Carolina, casualties of the company’s consolidation plan, WRAL reported this morning. WRAL noted that the terminations impacted “dozens” of Merck […]

Read More »

Novartis AG Scoops Up Pain Drug Firm Spinifex in $200 Million+ Deal

Spinifex Pharmaceuticals to be Acquired by Novartis STAMFORD, Connecticut and MELBOURNE, Australia, June 29, 2015 /PRNewswire/ —   US$200 million upfront payment plus undisclosed clinical development and regulatory milestones Expands Novartis‘ neuroscience portfolio with novel angiotensin II type 2 receptor antagonist technology for the treatment of chronic pain   Spinifex Pharmaceuticals, Inc. (“Spinifex”), a company […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom